Pembrolizumab

Pembrolizumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Metastatic Non-small Cell Lung Cancer With MTAP Deletion、Non-small Cell Lung Cancer、Carcinoma, Non-Small-Cell Lung、Metastatic Colorectal Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Pembrolizumab 研究

• VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

  I 期 / II 期招募中美国Puerto RicoNCT03556228

• Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

  I 期 / II 期招募中美国BrazilChile中国NCT06780111

• Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

  II 期招募中中国NCT06121700

• A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

  II 期招募中中国NCT06767800

• Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma

  II 期招募中SingaporeNCT06160843

• Histotripsy in Biliary Tract Cancer

  不适用招募中美国NCT07853690

• A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

  II 期招募中美国NCT07743190

• A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

  I 期招募中美国NCT03219450

• PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

  II 期招募中美国NCT06245889

• Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

  早期 I 期招募中美国NCT05553782

• Viscum Album for TNBC on Adjuvant Pembrolizumab

  IV 期招募中South KoreaNCT06920810

• Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

  II 期招募中美国NCT06745882

• Effect of Postbiotics on Microbiota and Systemic Immunomodulation of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC)

  II 期招募中意大利NCT07485296

• Pembrolizumab, Ibrutinib and Rituximab in PCNSL

  I 期 / II 期招募中美国NCT04421560

• A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

  I 期 / II 期招募中美国中国法国德国NCT06385080

• Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

  III 期招募中法国NCT04747054

• Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

  II 期招募中美国NCT05756569

• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

  II 期招募中美国NCT01042379

• Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

  I 期招募中美国NCT05603910

• A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

  II 期招募中中国NCT07622186

• A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

  II 期招募中美国NCT02621021

• A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

  II 期招募中中国NCT07054567

• Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer

  I 期 / II 期招募中South KoreaNCT04592211

• Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

  II 期招募中法国NCT05973864

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。